A brave new framework for glioma drug development
Hotchkiss K, Karschnia P, Schreck K, Geurts M, Cloughesy T, Huse J, Duke E, Lathia J, Ashley D, Nduom E, Long G, Singh K, Chalmers A, Ahluwalia M, Heimberger A, Bagley S, Todo T, Verhaak R, Kelly P, Hervey-Jumper S, de Groot J, Patel A, Fecci P, Parney I, Wykes V, Watts C, Burns T, Sanai N, Preusser M, Tonn J, Drummond K, Platten M, Das S, Tanner K, Vogelbaum M, Weller M, Whittle J, Berger M, Khasraw M. A brave new framework for glioma drug development. The Lancet Oncology 2024, 25: e512-e519. PMID: 39362262, DOI: 10.1016/s1470-2045(24)00190-6.Peer-Reviewed Original ResearchConceptsBrain tumorsBenefits of biopsyBrain tumor therapyLiquid biopsy technologiesTissue samplesPostoperative deficitsBiopsy techniqueBiopsy technologyEffective therapySurgical trialsClinical trialsTumor therapyResistance mechanismsTumorTherapyPatientsDrug developmentTissue analysisBrainTrialsTissueBiopsyGliomaRegulatory agenciesCASCADES, a novel SOX2 super‐enhancer‐associated long noncoding RNA, regulates cancer stem cell specification and differentiation in glioblastoma
Shahzad U, Nikolopoulos M, Li C, Johnston M, Wang J, Sabha N, Varn F, Riemenschneider A, Krumholtz S, Krishnamurthy P, Smith C, Karamchandani J, Watts J, Verhaak R, Gallo M, Rutka J, Das S. CASCADES, a novel SOX2 super‐enhancer‐associated long noncoding RNA, regulates cancer stem cell specification and differentiation in glioblastoma. Molecular Oncology 2024 PMID: 39323013, DOI: 10.1002/1878-0261.13735.Peer-Reviewed Original ResearchCancer stem cellsGlioma CSCsPresence of cancer stem cellsCancer stem cell compartmentPrimary malignant brain tumorGlioma cancer stem cellsMalignant brain tumorsCancer-specific mannerMedian survivalTumor recurrenceTreatment resistanceStem cell specificationRegulation of stemnessTumor developmentRegulation of Sox2Brain tumorsNeuronal lineageStem cellsGlioblastomaTherapeutic targetSOX2Cell RepositoryCell-specificTumorLong noncoding RNAs